News

On July 27, the 4th Biominds Talks Latin American Forum on Immunoassay Medicine was successfully held in Mexico City. The event was co-sponsored by Autobio and its Mexican partners in conjunction with the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). This event, which centered on immunoassay medicine, brought together over 140 experts, scholars, testing experts, and clinicians to discuss and exchange ideas on the future development trends of testing technology.

Mr. Fu Guangyu, Executive Vice President of Autobio, delivered a speech on behalf of the company. He stated that Autobio has been a leader in the field of in vitro diagnostics for 27 years, consistently prioritizing technological innovation in its strategic approach. The company's product portfolio encompasses immunology, microbiology, molecular biology, biochemistry, coagulation, and quality control products, among other domains. Autobio has established a comprehensive product matrix, serving over 110 countries and regions worldwide. He highlighted Mexico's significant potential for growth in the Latin American market. Autobio will continue to invest in the Latin American market and collaborate with its Latin American partners to promote the innovation and application of immunoassay technology, with the aim of enhancing local medical standards.

Professor Khosrow Adeli (former President of IFCC), Dr. Carolina Cucho Espinoza, Dr. Francisco Alberto Benavides Godinez, and Dr. José Javier Cárdenas, along with other experts and scholars, addressed strategies for preventing and controlling tuberculosis in Latin America, new applications of biomarkers, TORCH, TORCH, and other subjects. Dr. José Javier Cárdenas and other experts and scholars shared the latest research results and clinical practice experience in the fields of Latin American TB prevention and control strategies, new biomarkers, TORCH, magnetic particle chemiluminescence and new testing technologies. They also discussed how to optimize the testing process and improve the diagnostic accuracy through technological innovation.

The international sales team of Autobio presented a comprehensive overview of the company's suite of immunoassay testing solutions, with a particular emphasis on the clinical applications of TB-IGRA technology. Participants expressed that the forum provided valuable experience and cutting-edge perspectives for the development of immunoassay medicine in Latin America, and looked forward to more exchanges and cooperation in the future. During the forum, Autobio also demonstrated a variety of innovative testing equipment, which attracted many experts in the field. The on-site demonstration further solidified the participants' recognition of Autobio's technical prowess, paving the way for future collaborative projects.

The forum provided a platform for Latin American industry experts to engage in in-depth exchanges, as well as to discuss cutting-edge topics in the field of testing. These discussions yielded valuable insights into the actual needs of the local market for testing technology and the direction of development. The forum also provided an important reference for the targeted optimization of products and solutions. In the future, Autobio will continue to deepen the cooperation with strategic partners in Latin America, work together to promote the innovation and development of immunoassay testing technology, and jointly enhance the level of regional healthcare, contributing to the cause of global health.